Free triiodothyronine and free thyroxine hormone levels in relation to breast cancer risk: a meta-analysis

作者全名："Lei, Zhengwu; Zeng, Bin; Wu, Lina; Deng, Qin; Guo, Dan"

作者地址："[Lei, Zhengwu] Chongqing Med Univ, Affiliated Hosp 2, Hlth Management Ctr, Chongqing, Peoples R China; [Zeng, Bin; Wu, Lina; Deng, Qin; Guo, Dan] Chongqing Med Univ, Affiliated Hosp 2, Dept Breast & Thyroid Surg, 74 Linjiang Rd, Chongqing 400010, Peoples R China"

通信作者："Deng, Q; Guo, D (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Breast & Thyroid Surg, 74 Linjiang Rd, Chongqing 400010, Peoples R China."

来源：ENDOKRYNOLOGIA POLSKA

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000806740200003

JCR分区：Q4

影响因子：2.1

年份：2022

卷号：73

期号：2

开始页：309

结束页：315

文献类型：Article

关键词：free triiodothyronine; free thyroxine; breast cancer; meta-analysis

摘要："Introduction: The conflict between breast cancer (BC) and thyroid hormone (TH) has been studied for years. The purpose of the study was to summarise and analyse the available data on the relationship between TH and BC. Material and methods: The PubMed, EMBASE, Cochrane Library, and Google Scholar databases were searched to identify relevant studies. The mean difference (MD) with 95% confidence interval (CI) were calculated by fixed or random effects models to assess the effect sizes. Results: Thirteen eligible studies with 5957 participants were included in the meta-analysis. The result of this study indicates that there is a significant risk relationship between BC and thyroid hormones [free triiodothyronine (FT3): MD = 1.01 pmol/L, 95% CI: 0.32-1.70, free thyroxine (FT4): MD = 0.26 ng/dL, 95% CI: 0.13-0.38]. Conclusions: Compared with healthy controls, the positive risk of FT3 and FT4 is higher in BC."

基金机构：National Science Fund for Distinguished Young Scholars of China [81701709]

基金资助正文：This work was supported by the National Science Fund for Distinguished Young Scholars of China (81701709)